Types II, III and IV hypersensitivity
Antibody-mediated (type II), immune complex (type III) and T cell-mediated (type IV, with subtypes a to d) hypersensitivity, the diseases and drug reactions that illustrate each, complement patterns, and HLA-linked drug reactions.
Tier 1Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
Loading the rest of the note…
Finished reading?
Sources
- ASCIA drug (medication) allergy resources and terminologyAU/NZAustralasian Society of Clinical Immunology and Allergy (ASCIA), updated April 2026
- Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 updateClinical Pharmacology and Therapeutics (Phillips et al), 2018
- HLA-B*5701 screening for hypersensitivity to abacavir (PREDICT-1)New England Journal of Medicine (Mallal et al), 2008
- Delayed drug hypersensitivity reactionsAnnals of Internal Medicine (Pichler), 2003
- Abbas: Cellular and Molecular Immunology (10th ed.)Elsevier (Abbas, Lichtman and Pillai), 2022
- Robbins and Cotran Pathologic Basis of Disease (10th ed.)Elsevier (Kumar, Abbas and Aster), 2021
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Personal emails, About story and Australian-style copy